Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Stage 1 cT1b-T1cN0M0
Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2024-03-19

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT06318897

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Sacituzumab tirumotecan
Biological: Pembrolizumab
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-03-15

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 780

Registration Number: NCT06312137

Locations: 🇨🇳
Zhongshan Hospital of Fudan University ( Site 1325), Shangai, Shanghai, China
🇫🇷
Groupe hospitalier Paris saint Joseph. ( Site 1807), Paris, Ile-de-France, France
🇫🇷
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1810), Clermont-Ferrand, Puy-de-Dome, France

and more 124 locations

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Pemetrexed
Biological: Sacituzumab tirumotecan
Drug: Carboplatin
Drug: Antihistamine
Drug: H2 Receptor Antagonist
Drug: Acetaminophen (or equivalent)
Drug: Dexamethasone (or equivalent)
Drug: Steroid Mouthwash (dexamethasone or equivalent)

First Posted Date: 2024-03-12

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 520

Registration Number: NCT06305754

Locations: 🇨🇳
Anhui Provincial Cancer Hospital ( Site 3132), Hefei, Anhui, China
🇨🇳
Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107), Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118), Suzhou, Jiangsu, China

and more 88 locations

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer
Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Carboplatin
Drug: 177Lu-PSMA-617

First Posted Date: 2024-03-12

Last Posted Date: 2024-05-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT06303713

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma

Phase 1

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: tislelizumab
Radiation: radiotherapy

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Qiu Guoqin

Target Recruit Count: 30

Registration Number: NCT06303583

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Phase 2

Recruiting

Conditions: Non Small Cell Lung Cancer
EGFR Gene Mutation

Interventions: Drug: almonertinib
Drug: Carboplatin
Drug: Nab paclitaxel

First Posted Date: 2024-03-08

Last Posted Date: 2024-04-17

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 32

Registration Number: NCT06300424

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China